Biosimilar Trastuzumab in Clinical Trials: Differences or Not?

Area of Science:

• Oncology
• Pharmacology
• Clinical Trials

Background:

• Biologic agents are crucial in modern cancer combination therapies, particularly for breast cancer subtypes like HER2-positive.
• Trastuzumab, a HER2-targeted monoclonal antibody, has significantly improved survival rates in breast cancer.
• The expiration of trastuzumab's patent has led to the market entry of biosimilar versions.

Purpose of the Study:

• To provide insight into planning and conducting clinical trials to establish equivalence between biosimilar trastuzumab and its reference product.
• To elucidate the setup and outcomes of published clinical trials for biosimilar trastuzumab.

Main Methods:

• Review of clinical trial designs and outcomes for biosimilar trastuzumab.
• Analysis of endpoints used in biosimilar trials, including surrogate markers versus survival data.

Main Results:

• Multiple clinical trials have resulted in the approval of five distinct biosimilar trastuzumabs.
• These trials demonstrated similarity in efficacy and safety between biosimilars and the reference trastuzumab.
• However, current follow-up periods are short, and surrogate endpoints are often used instead of survival outcomes.

Conclusions:

• Biosimilar trastuzumabs have shown comparable efficacy and safety profiles to the originator product in clinical trials.
• The current evidence supports the use of biosimilar trastuzumab in HER2-positive breast cancer treatment.
• Further long-term studies are warranted to confirm survival benefits and fully evaluate the role of biosimilars in cancer therapy.